Combination therapy with vedolizumab and etanercept in a patient with pouchitis and spondylarthritis.

Authors:
Johannes Bethge, Silvia Meffert, Mark Ellrichmann, Claudio Conrad, Susanna Nikolaus, Stefan Schreiber
Year of publication:
2017
Volume:
4
Issue:
1
Issn:
2054-4774
Journal title abbreviated:
BMJ Open Gastroenterol
Journal title long:
BMJ open gastroenterology
Abstract:
Inflammatory bowel disease is frequently associated with spondylarthritis (SpA). It has been discussed that α4/β7 expressing lymphocytes are involved in the aetiology of SpA. We report a case of a successful combination therapy of vedolizumab (VDZ) and etanercept (ETA) in a patient with ulcerative colitis with pouchitis and SpA. In our case VDZ was effective for pouchitis and ineffective for SpA. The combination with ETA might be a useful treatment strategy to control both diseases and first indications suggest that it is safe. α4/β7 Expressing lymphocytes are most likely not associated in the aetiology of SpA.